Rigel Pharmaceuticals (RIGL) News Today $24.10 -3.36 (-12.24%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Rigel (RIGL) Receives a Hold from Piper SandlerNovember 15 at 6:06 AM | markets.businessinsider.comLos Angeles Capital Management LLC Increases Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Los Angeles Capital Management LLC boosted its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 34.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 74,502 shares of the biotechnologNovember 15 at 3:44 AM | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Up 4.8% on Analyst UpgradeNovember 15 at 2:25 AM | americanbankingnews.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by AnalystsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the four analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and two have assignedNovember 14 at 10:49 AM | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) StockPiper Sandler raised their target price on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a "neutral" rating in a report on Thursday.November 14 at 10:14 AM | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Expected to Rise, Citigroup Analyst SaysNovember 14 at 2:10 AM | americanbankingnews.comRigel Pharmaceuticals price target raised to $49 from $40 at CitiNovember 13, 2024 | markets.businessinsider.comRigel Pharmaceuticals (NASDAQ:RIGL) Reaches New 12-Month High on Analyst UpgradeNovember 13, 2024 | americanbankingnews.comRigel to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | prnewswire.comRigel’s Robust Financial Performance and Strategic Partnerships Drive Buy RatingNovember 10, 2024 | markets.businessinsider.comRigel Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 9, 2024 | markets.businessinsider.comRigel stock rallies 36% after Q3 earnings beatNovember 9, 2024 | msn.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | insidermonkey.comRigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 8, 2024 | finance.yahoo.comQ3 2024 Rigel Pharmaceuticals Inc Earnings Call TranscriptNovember 8, 2024 | gurufocus.comRigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comRigel Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | prnewswire.comRigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To ExpectNovember 7, 2024 | finance.yahoo.comRigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 5, 2024 | prnewswire.comRigel Pharmaceuticals (RIGL) to Release Quarterly Earnings on ThursdayRigel Pharmaceuticals (NASDAQ:RIGL) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comRigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business UpdateOctober 31, 2024 | prnewswire.comAssenagon Asset Management S.A. Takes Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Assenagon Asset Management S.A. bought a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 441,765 shares of the biotechnology company's stock, valued at approximatOctober 29, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Up 54.9% in OctoberRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 718,000 shares, an increase of 54.9% from the September 30th total of 463,500 shares. Based on an average daily volume of 135,900 shares, the short-interest ratio is presently 5.3 days. Currently, 4.2% of the shares of the company are sold short.October 27, 2024 | marketbeat.comRigel issues letter to doctors on fatal infection signal for GavretoOctober 25, 2024 | msn.comRigel Pharmaceuticals issues Dear Healthcare Provider letter for GavretoOctober 25, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)HC Wainwright reissued a "buy" rating and set a $57.00 price target on shares of Rigel Pharmaceuticals in a research report on Friday.October 25, 2024 | marketbeat.comRigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)October 24, 2024 | prnewswire.comRigel Pharmaceuticals (NASDAQ:RIGL) Raised to Strong-Buy at StockNews.comStockNews.com raised shares of Rigel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.October 18, 2024 | marketbeat.comOptime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®October 16, 2024 | globenewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC cut its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 79.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,200 shares of tOctober 16, 2024 | marketbeat.comRigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic PartnershipsOctober 10, 2024 | seekingalpha.comRigel Pharmaceuticals: Looking For More GrowthOctober 10, 2024 | seekingalpha.comSquarepoint Ops LLC Has $665,000 Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Squarepoint Ops LLC cut its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 86.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 80,910 shares of the biotechnology company's stock afterOctober 9, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Has $1.12 Million Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Healthcare of Ontario Pension Plan Trust Fund cut its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 90.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor oOctober 8, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comRenaissance Technologies LLC Decreases Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Renaissance Technologies LLC reduced its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 92.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,946 shares of the biotechnology company's stockOctober 6, 2024 | marketbeat.comRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 4, 2024 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is Stonepine Capital Management LLC's 9th Largest PositionStonepine Capital Management LLC reduced its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 70.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 305,000 shares of the biotechnology company's stock after sellingOctober 1, 2024 | marketbeat.comXTX Topco Ltd Has $234,000 Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)XTX Topco Ltd trimmed its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 90.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,515 shares of the biotechnology company'sSeptember 29, 2024 | marketbeat.comHigh Growth Tech Stocks in the United States to WatchSeptember 28, 2024 | sg.finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest UpdateRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 500,500 shares, a drop of 14.5% from the August 31st total of 585,300 shares. Approximately 2.9% of the company's stock are sold short. Based on an average daily volume of 170,100 shares, the short-interest ratio is currently 2.9 days.September 28, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Bank of New York Mellon CorpBank of New York Mellon Corp reduced its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 88.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 59,499 shares of the biotechnology company's stock after selling 464,517 shares durinSeptember 27, 2024 | marketbeat.comArmistice Capital LLC Decreases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Armistice Capital LLC decreased its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 89.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,624,000 shares of the biotechnology company's stock after selling 13,736,000 shares duringSeptember 26, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating and set a $15.00 price target on shares of Rigel Pharmaceuticals in a report on Friday.September 20, 2024 | marketbeat.comRigel to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 12, 2024 | prnewswire.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Passes Above 200-Day Moving Average of $11.37Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Cross Above 200 Day Moving Average of $11.37September 11, 2024 | marketbeat.comRigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AMLSeptember 5, 2024 | prnewswire.comBuy Rating Affirmed for Rigel with Positive Outlook on Asian Market Expansion and Solid NPV ValuationSeptember 3, 2024 | markets.businessinsider.comKissei Expands Relationship With Rigel To Commercialize Olutasidenib In Japan, Korea, TaiwanSeptember 3, 2024 | markets.businessinsider.comRigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Rigel Pharmaceuticals in a report on Tuesday.September 3, 2024 | marketbeat.com Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! RIGL Media Mentions By Week RIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼0.680.55▲Average Medical News Sentiment RIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼133▲RIGL Articles Average Week Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies G1 Therapeutics News Avid Bioservices News Novavax News Innoviva News OPKO Health News Ironwood Pharmaceuticals News Emergent BioSolutions News Sangamo Therapeutics News XOMA News Codexis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
